The emergence of mephedrone and other synthetic cathinones has offered challenges for lawmakers and regulatory businesses tasked with managing the proliferation of recent psychoactive substances. The dynamic character of synthetic drug generation, coupled with the ability of chemists to switch molecular constructions to evade lawful limitations, co